Pharma Companies Biohack Psychedelics for Safer Mental Health Therapies
Key Insights
Pharmaceutical companies are developing next-generation psychedelic drugs like R-MDMA, aiming for safer psychotherapy treatments with fewer side effects.
Mindstate (search) is using AI to understand how psychedelics affect the brain and has FDA approval for human trials of MSD-001 (Moxy), targeting specific serotonin receptors (search).
Companies are exploring synthetic versions of drugs like DMT to provide longer-lasting relief for depression (search), addressing the potential for unwanted "bad trips."
Pharmaceutical companies are actively engaged in experiments to create the next generation of psychedelic drugs, with the goal of transforming them into safer and more effective psychotherapy treatments. These efforts aim to harness the therapeutic potential of psychedelics while minimizing adverse effects.
Developing Safer Alternatives
MindMed (search) is at the forefront, developing an alternative to MDMA, known as R-MDMA. Early data suggests that R-MDMA exhibits fewer side effects compared to MDMA, enhancing its potential as a therapeutic drug. This is particularly significant given MDMA's Schedule I classification by the DEA, which denotes a dangerous drug with no accepted medical use, despite studies indicating its effectiveness in treating conditions like post-traumatic stress disorder (PTSD (search)) and depression (search).
Other companies are focusing on taming other psychedelic drugs, such as DMT, by creating synthetic versions that provide longer-lasting relief for individuals suffering from depression (search). The use of psychedelics in mental health, within controlled settings, has seen a resurgence of interest, despite ongoing debates about their potential to induce unwanted "bad trips."
AI-Driven Psychedelic Drug Development
Mindstate (search) is distinguishing itself by employing artificial intelligence to elucidate how psychedelic drugs impact the brain. This approach has yielded promising results, with the FDA recently approving human trials for their compound, MSD-001, also known as "Moxy." Moxy is designed to target specific serotonin receptors (search) with high specificity, thereby minimizing broader psychotropic effects, according to Microdose. In September 2024, Mindstate received approval to kick off human trials of MSD-001 by the US Food and Drug Administration.
According to Mindstate (search) CEO Dillan DiNardo, "Psychedelics are very promiscuous molecules... They're very effective, but they're scary and they're chaotic and they're unpredictable."
DiNardo told the Washington Post that "Moxy is not the entire medicine... Moxy is the first part of a number of different medicines that we’ll be making."
The Path Forward
While companies like Mindstate (search) and MindMed (search) have made strides, the journey to making synthetic psychedelics prescribable by healthcare practitioners is lengthy. Human trials are expected to span several years, and the ultimate effectiveness of these drugs remains uncertain. Nevertheless, advocates of psychedelic therapy view these developments as a meaningful step forward in the field.